...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....

...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....

...elevated LDL-C. Madrigal gained 3196 last September, when it acquired all of the assets of Via Pharmaceuticals Inc....

...worldwide rights to develop and commercialize the compound from Roche (see BioCentury, Jan. 5, 2009). Via Pharmaceuticals Inc....

...Co. Inc.'s 5-LO inhibitor, MK-0633, is in Phase II for chronic obstructive pulmonary disease (COPD). Via Pharmaceuticals Inc.'s...

...lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc....
...Jolla, Calif. University of California, San Francisco , Calif. University Paris Descartes , Paris, France Via Pharmaceuticals Inc....

...compared with vehicle. Next steps include testing the DGAT1 inhibitor in humanized mice. Roche and Via Pharmaceuticals Inc....

...of R&D at Via Pharmaceuticals Inc. "It's a very complex area involving triglyceride biosynthesis, absorption and clearance." Via Pharmaceuticals...
...of Cambridge , Cambridge, U.K. The University of Sydney , Sydney, New South Wales, Australia Via Pharmaceuticals Inc....

...$1.3 million in a note offering. The notes bear 15% interest and mature in December. Via Pharmaceuticals Inc....

...function, missed the co-primary endpoints in patients with mild to moderate Alzheimer's disease (AD) 3/31/10 Via Pharmaceuticals Inc....